10.11.2014 13:44:18
|
Dendreon Q3 Loss Narrows - Quick Facts
(RTTNews) - Dendreon Corp. (DNDN), a biotechnology firm focused on cancer treatments, reported third-quarter net loss of $22.1 million or $0.14 per share, narrower than $67.2 million or $0.44 per share in the comparable quarter last year.
On average, 13 analysts polled by Thomson Reuters expected the company to report a loss of $0.20 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenue increased to $73.12 million from $68.00 million a year earlier, while 11 analysts estimated revenues of $75.27 million for the quarter.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Dendreon Corp.mehr Nachrichten
Keine Nachrichten verfügbar. |